Svas Biosana SpA
MIL:SVS
Relative Value
The Relative Value of one SVS stock under the Base Case scenario is 17.56 EUR. Compared to the current market price of 8.42 EUR, Svas Biosana SpA is Undervalued by 52%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
SVS Competitors Multiples
Svas Biosana SpA Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IT |
S
|
Svas Biosana SpA
MIL:SVS
|
44.6m EUR | 0.3 | 6.6 | 3.3 | 4.9 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY | 10.5 | 38.5 | 27.9 | 33.5 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57.9B USD | 0 | 0 | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.4B CHF | 3.7 | 39.8 | 15.3 | 29.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
104.9B DKK | 3.8 | 26.5 | 13.8 | 16.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.4B USD | 3.1 | 30.2 | 13 | 17.9 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.8B GBP | 2.7 | 37.5 | 14.8 | 25.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.4B CNY | 9.3 | 25.7 | 23.2 | 23.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD | 1.2 | -16.8 | 17.6 | 56.9 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
874B JPY | 6.7 | 49.4 | 23.3 | 31.7 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
4.7B USD | 3 | 20.1 | 12.8 | 15.7 |